Nutex Health, Inc. (NUTX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-345.7%

-$456.06

vs $185.60 price

Levered DCF

$866.53

After debt service

Piotroski score

6 / 9

Average

Altman Z-score

4.12

Safe zone

Rating

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	14.79×	3.1×	-2.6×	-2.84×	18.42×	8.2×	61.48×	-18,750×
P/B	3.18×	1.1×	1.94×	12.57×	21.3×	10.13×	43.87×	-1,799.23×
P/S	1.2×	0.34×	0.48×	5.49×	7.37×	3.17×	12.8×	1,970.8×
EV / EBITDA	4.22×	3.08×	-25.57×	-3.65×	14.1×	6.29×	35.54×	-3,209.47×
Gross margin	50.8%	40.9%	14.0%	7.0%	54.1%	57.5%	58.6%	62.8%
Operating margin	31.5%	27.2%	-12.8%	-185.4%	51.4%	55.9%	35.8%	-61.5%
Net margin	8.1%	10.9%	-18.5%	-193.7%	40.0%	38.7%	21.6%	-205.9%
Current ratio	3.41×	2.08×	1.56×	1.79×	4.09×	4.31×	0.63×	0.29×
Debt / equity	1.07×	2.33×	4.49×	2.79×	1.56×	1.75×	4.24×	-0.92×
Interest coverage	12.4×	6.55×	-1.95×	-32.55×	27.48×	23.81×	9.83×	-7.65×
Dividend yield	7.1%	4.0%	4.4%	4.3%	5.9%	6.8%	1.5%	0.0%
Payout ratio	104.9%	12.3%	-11.4%	-12.1%	108.9%	55.7%	90.3%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	21.5%	35.7%	-74.5%	-443.1%	115.6%	123.5%	73.9%	187.9%
Return on invested capital	25.9%	20.9%	-7.9%	-102.2%	45.7%	51.4%	20.3%	714.8%
Return on assets	7.7%	8.0%	-11.5%	-98.4%	33.6%	34.3%	11.7%	-626.2%
Free cash flow yield	23.5%	12.9%	-6.9%	3.0%	5.6%	2.9%	-1.6%	-0.0%
Earnings yield	6.8%	32.3%	-38.5%	-35.3%	5.4%	12.2%	1.7%	-0.1%
Enterprise value	$1.2B	$458.3M	$372.8M	$1.4B	$2.6B	$993.7M	$1.4B	$2.7B
Net debt / EBITDA	0.58×	2×	-17.4×	-0.59×	0.78×	0.79×	2.94×	-1.5×
Cash conversion cycle (days)	97	165	55	61	91	122	128	-338